Norah Terrault, MD, MPH

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Norah Terrault, MD, MPH

Assistant Professor, Department of Medicine (Gastroenterology), UCSF

Phone: (415) 353-2318 (appts)
Box 0538, UCSF
San Francisco, CA 94143-0538

View on UCSF Profiles

Cancer Center Membership

Associate Member ยป Non-aligned

Education

University of Alberta, MD, 1984-87
University of Toronto, FRCPC, 1988-92, Internal Medicine
University of Toronto, FRCPC, 1992-94, Gastroenterology
University of California, Berkeley, MPH, 1996-97, Epidemiology


Professional Experience

  • 1987-88 Comprehensive internship, University of Toronto
  • 1988-91
    Residency in Internal Medicine, University of Toronto
  • 1991-93
    Residency in Gastroenterology, University of Toronto
  • 1993-94
    Clinical Fellowship, University of Toronto
  • 1994-97
    Research Fellowship, University of California San Francisco
  • 1997-2002
    Adjunct Assistant Professor, Dept. of Medicine/Gastroenterology, University of California San Francisco
  • 2002-present
    Assistant Professor, Dept. of Medicine/Gastroenterology, University of California San Francisco

Honors & Awards

  • 1991
    Dr. D.H. Cowan, University of Toronto Teaching Award
  • 1992
    CAG Residents' Presentation Award
  • 1994
    CASL Presentation Award
  • 1994-96
    Canadian Liver Foundation Fellowship Award
  • 1996
    Canadian Liver Foundation Fellowship Award (declined)
  • 1996
    Medical Research Council of Canada Fellowship Award (declined)
  • 1996-8
    Dr. Saul Krugman Career Development Award
  • 1997-9
    Jan Albrecht Career Development Award

Selected Publications

  1. Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. Liver Transpl. 2016 Jan; 22(1):24-33.
    View on PubMed
  2. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016 Jan; 63(1):261-83.
    View on PubMed
  3. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015 Nov; 64(11):1824-33.
    View on PubMed
  4. Facility- and Patient-Level Factors Associated with Esophageal Variceal Screening in the USA. Dig Dis Sci. 2016 Jan; 61(1):62-9.
    View on PubMed
  5. New Therapies, Evidence, and Guidance in Hepatitis C Management: Expert Practices and Insights from an Educational Symposium at the AMCP 27th Annual Meeting Expo. J Manag Care Spec Pharm. 2015 Sep; 21(9):S1-S17.
    View on PubMed
  6. Diabetes and Prediabetes in Patients with Hepatitis B Residing in North America. Hepatology. 2015 Aug 8.
    View on PubMed
  7. The corrected donor age for hepatitis C virus-infected liver transplant recipients. Liver Transpl. 2015 Aug; 21(8):1022-30.
    View on PubMed
  8. Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. Transplantation. 2015 Aug; 99(8):1644-51.
    View on PubMed
  9. Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C-Infected Patients With Compensated and Decompensated Cirrhosis. Hepatology. 2015 Sep; 62(3):715-25.
    View on PubMed
  10. Current Management of Hepatitis C Virus: Regimens for Peri-Liver Transplant Patients. Clin Liver Dis. 2015 Nov; 19(4):669-88.
    View on PubMed
  11. Severe Cholestatic Hepatitis C in Transplant Recipients: No Longer a Threat to Graft Survival. Clin Gastroenterol Hepatol. 2015 Nov; 13(11):2002-4.
    View on PubMed
  12. Difficult-to-cure populations with chronic hepatitis c: Vanishing in the direct-acting antiviral era? Hepatology. 2015 Jul; 62(1):4-7.
    View on PubMed
  13. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
    View on PubMed
  14. Hepatitis C Genotype Influences Post-liver Transplant Outcomes. Transplantation. 2015 Apr; 99(4):835-40.
    View on PubMed
  15. Treatment of hepatitis C in liver transplant patients: Interferon out, direct antiviral combos in. Liver Transpl. 2015 Apr; 21(4):423-34.
    View on PubMed
  16. Hepatitis C direct antiviral drugs and hepatic decompensation in patients with advanced cirrhosis: culprit or innocent bystander? Dig Dis Sci. 2015 Apr; 60(4):806-9.
    View on PubMed
  17. Total 25(OH) vitamin D, free 25(OH) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction. Liver Int. 2015 Oct; 35(10):2294-300.
    View on PubMed
  18. Human immunodeficiency virus and liver transplantation: Hepatitis C is the last hurdle. Hepatology. 2015 May; 61(5):1747-54.
    View on PubMed
  19. High Rate of Hospital Admissions Among Patients with Cirrhosis Seeking Care in US Emergency Departments. Dig Dis Sci. 2015 Jul; 60(7):2183-9.
    View on PubMed
  20. Clinician assessments of health status predict mortality in patients with end-stage liver disease awaiting liver transplantation. Liver Int. 2015 Sep; 35(9):2167-73.
    View on PubMed

Go to UCSF Profiles, powered by CTSI